GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.
Financial Results:
Glaxosmithkline Pharmaceuticals Ltd reported Revenues for Q2FY25 of ₹1,011.00 Crores up from ₹957.00 Crore year on year, a rise of 5.64%.
Total Expenses for Q2FY25 of ₹706.00 Crores up from ₹686.00 Crores year on year, a rise of 2.92%.
Consolidated Net Profit of ₹252.00 Crores up 15.6% from ₹218.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹14.91, up 16.12% from ₹12.84 in the same quarter of the previous year.